News Vanda ends 40-year hiatus for new motion sickness drugs The FDA has delivered some end-of-year cheer to Vanda Pharma after approving Nereus, its drug for the prevention of motion sickness.
News Vanda slams FDA rejection of gastroparesis drug The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious response from the company.
News NHS "isn't delivering equitable care for rare diseases" A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.